반응식
Cl[C:2]1[N:7]=[CH:6][C:5]([CH2:8][O:9][CH:10]2[CH2:15][CH2:14][N:13]([C:16]([O:18][C:19]([CH3:22])([CH3:21])[CH3:20])=[O:17])[CH2:12][CH2:11]2)=[CH:4][CH:3]=1.[CH3:23][S:24]([C:27]1[CH:28]=[C:29]2[C:33](=[CH:34][CH:35]=1)[NH:32][CH:31]=[CH:30]2)(=[O:26])=[O:25]>>[C:19]([O:18][C:16]([N:13]1[CH2:14][CH2:15][CH:10]([O:9][CH2:8][C:5]2[CH:6]=[N:7][C:2]([N:32]3[C:33]4[C:29](=[CH:28][C:27]([S:24]([CH3:23])(=[O:26])=[O:25])=[CH:35][CH:34]=4)[CH:30]=[CH:31]3)=[CH:3][CH:4]=2)[CH2:11][CH2:12]1)=[O:17])([CH3:22])([CH3:21])[CH3:20]참가 물질
3
실험 절차
The title compound was prepared by following a procedure described in Intermediate-27 by using tert-butyl 4-((6-chloropyridin-3-yl)methoxy)piperidine-1-carboxylate and 5-(methylsulfonyl)-1H-indole (0.410 g, 27.70%); MS: 386.32 (M−100).
출처 및 근거
- ORD 기록
- ord-38c463916d614b81a2ef8995c6eb05bd
- 출처 데이터셋
- uspto-grants-2015_04
- 특허 번호
- US09000175B2
연결된 노트
불러오는 중…